Day: November 14, 2023

Total revenue for the first nine months of 2023 was approximately $2.35 million compared to approximately $1.89 million in the first nine months of 2022 Implemented certain cash management initiatives, including restructuring U.S. operations by reducing headcount during the third quarter of 2023 Signed preferred stock purchase agreement with a potential strategic investor in October 2023 Entered into a warrant inducement agreement with an institutional investor in October 2023 Subsidiaries Curetis GmbH in Germany and Ares Genetics GmbH in Austria filed for insolvency under German and Austrian laws, respectively, in November 2023ROCKVILLE, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

FREMONT, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) — Actelis Networks, Inc. (NASDAQ: ASNS) (“Actelis” or the “Company”), a market leader in cyber-hardened, rapid deployment Hybrid-Fiber networking solutions for wide area IoT applications, today reported financial results for the fiscal third quarter and nine months ended September 30, 2023. “During the third quarter of 2023 we have seen a good level of interest in our newly launched products, that are providing solutions for rapid deployment, cost effective and secure networking for critical infrastructure for our IoT and Federal customers. We have also seen interest from several large network operators in our new solutions aiming at connecting millions of buildings and customers in multi-tenant-building (MDU)”, said Tuvia Barlev, Chairman and CEO of Actelis. “Those products are expected...

SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) — Presidio Property Trust, Inc. (Nasdaq: SQFT, SQFTP, SQFTW) (the “Company”), an internally managed, diversified real estate investment trust (“REIT”), today reported earnings for its quarter ended September 30, 2023. Quarter Ended September 30, 2023, Financial Results Net income attributable to the Company’s common stockholders for the three months ended September 30, 2023 was approximately $20.96 million, or $1.77 per basic and diluted share, compared to a net loss of approximately $1.30 million, or $(0.11) per basic and diluted share for the three months ended September 30, 2022. The change in net income attributable to the Company’s common stockholders was a result of:During September, the Company’s sponsored SPAC Murphy Canyon Acquisition Corp. completed its business combination...

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, Nov. 14, 2023 (GLOBE NEWSWIRE) — Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTCQX: ATCMF) today announced its financial results for the three months ended September 30, 2023, posting a net loss of $1.1 million. Production for the period at Atico’s El Roble mine totaled 3.8 million pounds (“lbs”) of copper and 2,724 ounces (“oz”) of gold in concentrate at a cash cost(1) of $1.97 per payable pound of copper(2). Fernando E. Ganoza, CEO and Director, commented, “During the quarter we saw a significant improvement in ore production and grades at El Roble when compared to previous quarters in the year. However, these operational gains were almost completely offset by strong appreciation of the Colombian peso along with weaker...

BOCA RATON, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) — FlexShopper, Inc. (Nasdaq:FPAY) (“FlexShopper”), a leading national online lease-to-own (“LTO”) retailer and payment solution provider for underserved consumers, today announced its financial results for the quarter ended September 30, 2023. Results for Quarter Ended September 30, 2023, vs. Quarter Ended September 30, 2022:Total fundings increased 10.7% to $28.9 million from $26.1 million consisting of gross lease originations decreasing 10.8% from $15.7 to $14.0 million, loan participations decreasing 99.3% from $10.4 million to $77 thousand, and loan originations increasing from $0 to $14.8 million   Total net lease and loan revenues and fees increased 20.3% to $31.4 million from $26.1 million   Gross profit increased 164.1% to $16.9 million from $6.4 million   Adjusted EBITDA1...

Midland, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) — Third Quarter 2023 HighlightsRental revenue of $27.7 million, an increase of 49% when compared to the third quarter of 2022 and 15% when compared to the second quarter of 2023. Net income of $2.2 million, or $0.18 per basic share, as compared to a net loss of $80,000 in the third quarter of 2022 and net income of $504,000 in the second quarter of 2023. Adjusted EBITDA of $11.8 million, compared to $7.7 million in the third quarter of 2022 and $9.9 million in the second quarter of 2023. Please see Non-GAAP Financial Measures – Adjusted EBITDA, below.MIDLAND, Texas November 14, 2023 (GLOBE NEWSWIRE) Natural Gas Services Group, Inc. (“NGS” or the “Company”) (NYSE:NGS), a leading provider of natural gas compression equipment, technology and services to the energy industry,...

SEATTLE, Nov. 14, 2023 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced third quarter financial results for the period ended September 30, 2023 and provided recent business highlights..  “Our commitment to advancing targeted alpha-particle therapies against neuroendocrine tumors remains steadfast as we have completed dosing of the first patient in the Phase 1/2a clinical trial of [212Pb]VMT-α-NET,” said Thijs Spoor, Perspective Therapeutics’ CEO. “In addition, we completed recruitment for the first patient cohort in the Company-sponsored Phase 1/2a dose escalation/dose expansion clinical trial evaluating [212Pb]VMT01 for the treatment of histologically confirmed melanoma. We are nearing completion of the imaging portion of the clinical trial evaluating the suitability of [203Pb]VMT01...

–  Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of dose-dependent anti-tumor and biomarker activity –   –  Safety data indicate WTX-124 is generally well tolerated through cohort 4 (12 mg), with a wide therapeutic index supportive of continued dose escalation –   –  Additional interim WTX-124 monotherapy data and recommended dose for expansion expected in the first half of 2024 –      –  Announcing the addition of WTX-518, a novel conditionally activated IL-18 INDUKINE™ molecule designed to promote activation of immune cells in the tumor microenvironment resulting in antitumor immunity, to Werewolf’s pipeline of preclinical development candidates –   WATERTOWN, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc....

MOUNTAIN VIEW, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) — Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update. Recent Business UpdatesGenerated total revenue of $12.9 million, representing flat sequential quarter revenue and a decrease of 12% year-over-year Cyclo G6® product family revenue in the third quarter of $3.0 million, representing a decrease 12% year-over-year due to reduced systems salesSold 13,200 Cyclo G6 probes, representing a 3% revenue increase and 3% unit decrease year-over-year Sold 27 Cyclo G6 Glaucoma Laser Systems, compared to 41 in the second...

Hallmark Financial Services, Inc.Hallmark Financial Services, Inc.DALLAS, Nov. 14, 2023 (GLOBE NEWSWIRE) — Hallmark Financial Services, Inc. (“Hallmark”) (NASDAQ: HALL) today filed its Form 10-Q and announced financial results for the third quarter and nine months ended September 30, 2023.  Third Quarter   Year-to-Date  2023 2022   2023 2022$ in millions:          Net loss from continuing operations $ (16.7 ) $ (29.2 )   $ (73.7 ) $ (104.9 )Net (loss) income from discontinued operations $ (4.8 ) $ 1.1     $ 1.1   $ 4.2  Net loss $ (21.5 ) $ (28.1 )   $ (72.6 ) $ (100.7 )Operating loss from continuing operations(1) $ (11.7 ) $ (20.6 )   $ (29.1 ) $ (69.2 )           $ per diluted share (2):          Net loss from continuing operations $ (9.16 ) $ (16.08 )   $ (40.53 ) $ (57.72 )Net (loss)...